HomeHome SearchSearch MenuMenu Our productsOur products Ask an ExpertAsk an Expert

There's a new HER2-positive breast cancer treatment on the block

by , 26 July 2017
There's a new HER2-positive breast cancer treatment on the block
The US Food and Drug Administration (FDA) has just approved a new early-stage breast cancer treatment called Nerlynx (neratinib). According to the FDA, Nerlynx is the first extended adjuvant treatment of early-stage, HER2-positive breast cancer.

Extended adjuvant treatment is a type of therapy that patients take after an initial treatment to lower their risk of the cancer coming back even further. Nerlynx was designed for adult breast cancer patients who've been previously treated with a regimen including trastuzumab. Keep reading for more...

HER2-positive breast cancers are aggressive tumours that can spread to other parts of your body...

Richard Pazdur, director of the FDA’s Oncology Center of Excellence, explains that HER2-positive breast cancers are aggressive tumours that can spread to other parts of the body. Now that Nerlynx has been approved, patients with this type of breast cancer can help stop the cancer from coming back.

***

MUST-READ!

Imagine your body starts to sort out its health problems on its own!

 
There are dozens of testimonies of this using Mother Nature's CBD oil...

CBD oil contains all 21 of the amino acids your body needs to stay in tip-top shape and is the only perfectly balanced combination of omega-3 to omega-6 essential fatty acids (EFAs) on the planet!
 
Amino acids and EFAs are the building blocks to life. They keep you alive by rebuilding and producing new cells in your body.

The results are astonishing when CBD oil is used to treat:

Click here for more details...
 
***
 

Nerlynx works by blocking several enzymes that promote breast cancer cell growth

So how does Nerlynx work? According to the FDA, it’s a kinase inhibitor that works by blocking several enzymes that promote breast cancer cell growth. To test the safety and efficacy of Nerlynx, FDA researchers studied its effects on 2,840 patients with early-stage, HER2-positive breast cancer in a randomised trial. They noted that these patients had completed their treatment with trastuzumab within the previous two years.
 
The study specifically measured the amount of time after the start of the trial that it took for the cancer to come back or for death to occur from any cause. The researchers discovered after two years that 94.2% of patients treated with Nerlynx hadn’t experienced cancer recurrence or death compared with 91.9% of those who received a placebo.
 
However, the researchers did note that Nerlynx can have side effects such as diarrhoea, nausea, vomiting, fatigue, abdominal pain and swelling, rash, swollen and sore mouth, muscle spasms, indigestion, decreased appetite, liver damage, dry skin, nail disorder, weight loss and urinary tract infection.
 
For more information on this new HER2-positive breast cancer treatment, speak to your primary care physician.

Vote article

There's a new HER2-positive breast cancer treatment on the block
Rating:
Note: 5 of 1 vote

Related articles




Ask our Experts a Question

Linda Weech
Vanessa Jackson (BSc Anat&Phys, AEA, NLP)
Karin Iten, FSP Nutritionals, BA (Hons)
Nicqui Grant
Annabel Koffman

Related articles


Watch And Learn



Related Products

Resources